Research location

Qingdao

Shandong, China

Published trials205

Site observations220

Linked trials published205

Page1 / 5

Research activity in Qingdao

Shandong, China

CureCurrent currently publishes aggregate city-level research activity for this location: 205 trials and 220 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Qingdao

205 linked trials · page 1 of 5

Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid ArthritisNCT07796516 · 2026-09-01 · 2 site observations

Monoamine Oxidase B PET/CT in Various MAO-B-Related DiseaseNCT07685873 · 2026-06-25 · 1 site observation

Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLDNCT07632677 · 2026-05-15 · 1 site observation

RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLCNCT07541521 · 2026-04-13 · 1 site observation

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)NCT07416474 · 2026-04-03 · 1 site observation

Phase II Trial of RC1416 Injection in AsthmaNCT07403487 · 2026-03-10 · 1 site observation

Phase II Study of RC1416 Injection in COPDNCT07402551 · 2026-03-06 · 1 site observation

A Study of DXC014 in Patients With Advanced Solid Tumors.NCT07177937 · 2026-03-03 · 1 site observation

Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLCNCT07528066 · 2026-03-02 · 1 site observation

A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid AsthmaNCT07436949 · 2026-03-02 · 1 site observation

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionNCT07063745 · 2026-01-02 · 1 site observation

A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) MetastasesNCT07143045 · 2025-12-29 · 1 site observation

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsNCT07185997 · 2025-12-17 · 1 site observation

[18F]NIDF PET Imaging in Tau-related DiseasesNCT07306598 · 2025-11-01 · 1 site observation

JS207 Combination Therapy in Triple-negative Breast CancerNCT07045311 · 2025-09-17 · 1 site observation

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)NCT06926868 · 2025-09-11 · 1 site observation

[18F]FT8 PET Imaging in Immunoglobulin Light Chain AmyloidosisNCT07232459 · 2025-07-21 · 1 site observation

Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast CancerNCT07285382 · 2025-06-25 · 1 site observation

An Observational Study on the Safety and Efficacy of Henagliflozin in Chinese Patients With Type 2 DiabetesNCT06959030 · 2025-06-19 · 1 site observation

A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation TherapyNCT07010263 · 2025-06-13 · 1 site observation

A Study of HS-20094 in Overweight or Obese ParticipantsNCT07057674 · 2025-04-16 · 1 site observation

Clinical Study of 18F-Labeled FAPI-04 in PET Imaging of Breast CancerNCT06916338 · 2025-04-11 · 1 site observation

Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast CancerNCT06916637 · 2025-04-09 · 1 site observation

Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or DfNCT07348302 · 2025-04-02 · 1 site observation

Alpha-Synuclein PET/CT in Various α-Syn-Related DiseaseNCT06949670 · 2025-04-01 · 1 site observation

Effect of the Home-based Digital-assisted Dyadic Tai Chi (HDTC) Training Program Among Sedentary Individuals With HF and Their Caregivers: a Randomized Controlled TrialNCT06876441 · 2025-04-01 · 1 site observation

TQC2731 Clinical Trial for the Treatment of Severe Asthma With InjectionNCT06829784 · 2025-03-21 · 1 site observation

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1NCT06767514 · 2025-02-27 · 1 site observation

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerNCT07673029 · 2025-01-10 · 1 site observation

Study on Human Bioequivalence of Triprerelin Acetate for InjectionNCT06683066 · 2024-12-04 · 1 site observation

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.NCT06629779 · 2024-10-22 · 1 site observation

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C MutationNCT06416410 · 2024-08-07 · 1 site observation

Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung CancerNCT06514118 · 2024-04-17 · 3 site observations

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy FailureNCT06300177 · 2024-03-28 · 1 site observation

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC PatientsNCT06155084 · 2023-12-26 · 1 site observation

A Study of YL202 in Selected Patients With Advanced Solid TumorsNCT06107686 · 2023-12-15 · 1 site observation

Pan-Amyloid PET/CT in Various Amyloid-Related DiseaseNCT07130565 · 2023-11-01 · 1 site observation

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsNCT05899608 · 2023-10-26 · 1 site observation

An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's DiseaseNCT05908695 · 2023-08-31 · 2 site observations

SHengXIaN-QuYu DEcoction in Heart Failure With Reduced and Mildly Reduced Ejection FractionNCT05583773 · 2023-03-29 · 1 site observation

A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast CancerNCT05851014 · 2022-01-14 · 1 site observation

Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast CancerNCT04790305 · 2021-06-18 · 1 site observation

Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease PatientsNCT06690970 · 2020-09-01 · 1 site observation

Study on Multimodal Imaging and Molecular Imaging Techniques in Degenerative DementiaNCT06534658 · 2020-07-30 · 1 site observation

A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer PatientsNCT03258320 · 2015-01-01 · 1 site observation

Beta Amyloid PET/CT in Various Aβ-Related DiseaseNCT06725706 · 2012-09-01 · 1 site observation

The Chinese Familial Alzheimer's NetworkNCT03657732 · 2005-01-10 · 3 site observations

China Cognition and Aging StudyNCT03653156 · 2000-01-01 · 3 site observations

Efficacy of Lipoic Acid on Chronic Ischemic Heart Failure PatientsNCT07725484 · 2026-11-01 · 1 site observation

NOT_YET_RECRUITING

A Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy ParticipantsNCT06506175 · 2026-07-01 · 1 site observation

NOT_YET_RECRUITING

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.